Keyphrases
Cetuximab
100%
Radioimmunotherapy
100%
Single Institution
100%
Adenoid Cystic Carcinoma
100%
Combined Treatment
100%
Local Control
66%
Overall Survival
33%
Progression-free Survival
33%
Vascular Endothelial Growth Factor Receptor (VEGFR)
33%
Re-irradiation
33%
Controlled Experiment
16%
Potential Gains
16%
Dysphagia
16%
High Dose
16%
Dose Effect
16%
Receptor Expression
16%
Treatment Response
16%
Control Rate
16%
Kaplan-Meier Estimator
16%
Median Overall Survival
16%
Local Treatment
16%
Baseline Characteristics
16%
Mucositis
16%
Remission Rate
16%
Combination Regimen
16%
Treatment Parameters
16%
Control Response
16%
Distant Failure
16%
Growth Factor Receptor Inhibitors
16%
Radiation Sensitization
16%
6-cycles
16%
Clinical Situation
16%
Medicine and Dentistry
Cylindroma
100%
Radioimmunotherapy
100%
Cetuximab
100%
Overall Survival
50%
Progression Free Survival
33%
Growth Factor Receptor
33%
Re-Irradiation
33%
Endothelial Cell Growth Factor
33%
Drug Megadose
16%
Spontaneous Remission
16%
Treatment Response
16%
Receptor Expression
16%
Kaplan Meier Method
16%
Controlled Clinical Trial
16%
Mucositis
16%
Plummer-Vinson Syndrome
16%
Radiosensitization
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adenoid Cystic Carcinoma
100%
Cetuximab
100%
Overall Survival
75%
Progression Free Survival
50%
Growth Factor Receptor
50%
Endothelial Cell Growth Factor
50%
Controlled Clinical Trial
25%
Mucosa Inflammation
25%
Remission
25%
Dysphagia
25%